



To,  
The Board of Directors,  
**Vivanza Biosciences Limited**  
Ahmedabad

We have reviewed the accompanying statement of Unaudited Financial Results (the statement) of **M/s Vivanza Biosciences Limited** ("the Company") for the first quarter ended 30<sup>th</sup> June, 2017 attached herewith being submitted by company to the stock exchanges viz. BSE pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015.

This statement is the responsibility of the company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these statements based on our review. Attention is drawn to the fact that the figures of the corresponding quarter ended 30<sup>th</sup> June, 2016, and year ended 31<sup>st</sup> March, 2017 including the reconciliation of profit under Ind AS for the year ended 31<sup>st</sup> March, 2017 with profit reported under previous GAAP as reported in this statement, have been approved by the company's Board of Directors, but have not been subjected to review.

We conducted our review in accordance with the standard on review engagement (SRE) 2410, Review Financial Information performed Auditor of Entity, issued by the institute of Chartered Accountant of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and accordingly / we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with applicable Indian Accounting standards (Ind AS) prescribed under section 133 of the companies act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be Disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015 read with

Address : 101, Parishram, 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Roads, Navrangpura, Ahmedabad - 380009  
☎ 079-40037372 ✉ [gmca1973@gmail.com](mailto:gmca1973@gmail.com)



CA

**G M C A & Co.**

Chartered Accountants

SEBI circular number CIR/CFD/FAC/62/2016 Dated 5<sup>TH</sup> July 2016 including the manner in which it is to be disclosed or that is contains any material misstatement.

For, G M C A & CO.  
Chartered Accountants  
FRN: 109850W



*Amin G. Shaikh*

CA. Amin G. Shaikh  
Partner

Membership No: 108894

Place: Ahmedabad

Date: 22<sup>nd</sup> August, 2017

Address : 101, Parishram, 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Roads, Navrangpura, Ahmedabad - 380009

☎ 079-40037372 ✉ [gmca1973@gmail.com](mailto:gmca1973@gmail.com)

## VIVANZA BIOSCIENCES LIMITED

(Formerly Known as IVEE INJECTAA LTD )

Registered Office: 702 "A" wing, Ashoka Chambers, Rasala Marg, Ellisbridge , Ahmedabad 380 006.  
CIN : L24110GJ1982PLC005057

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017.

(Rs. in Lacs except per share data)

Particulars	Quarter Ended				Year Ended
	30/06/2017	31/03/2017	30/06/2016	31/03/2017	
	Unaudited	Audited	Unaudited	Audited	
<b>1 Income from Operations</b>					
(a) Revenue from operations	264.15	252.60	0.00	347.47	
(b) Other Income	0.11	4.12	0.00	4.53	
<b>Total Income</b>	<b>264.26</b>	<b>256.72</b>	<b>0.00</b>	<b>352.00</b>	
<b>2 Expenses</b>					
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	
(b) Purchase of stock-in-trade	64.32	365.08	0.00	487.77	
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	162.64	-138.99	0.00	-181.00	
(d) Employee benefits expense	9.13	-2.10	9.93	30.47	
(e) Finance Costs	8.56	4.25	0.00	4.25	
(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	
(g) Other expenses	11.55	8.98	4.45	26.39	
<b>Total Expenses</b>	<b>256.20</b>	<b>237.22</b>	<b>14.38</b>	<b>367.88</b>	
<b>3 Profit/(loss) before exceptional items and tax (1-2)</b>	<b>8.06</b>	<b>19.50</b>	<b>-14.38</b>	<b>-15.88</b>	
4 Exceptional Items	0.00	0.00	0.00	0.00	
<b>5 Profit/(Loss) before tax (3-4)</b>	<b>8.06</b>	<b>19.50</b>	<b>-14.38</b>	<b>-15.88</b>	
<b>6 Tax Expense</b>					
(a) Current tax	0.00	0.00	0.00	0.00	
(b) Deferred tax	0.00	0.00	0.00	0.00	
<b>Total Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	
<b>7 Profit / (Loss) for the period from continuing operations (5-6)</b>	<b>8.06</b>	<b>19.50</b>	<b>-14.38</b>	<b>-15.88</b>	
8 Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	
<b>10 Profit (Loss) from discontinuing operations (after tax)(8-9)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	
<b>11 Other Comprehensive Income</b>					
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	
<b>B (i) Items that will be reclassified to profit or loss</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	
<b>Other Comprehensive Income for the period</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	
<b>12 Total Comprehensive Income for the period</b>	<b>8.06</b>	<b>19.50</b>	<b>-14.38</b>	<b>-15.88</b>	
13 Paid-up equity share capital (Face value of ` 10/- each)	400	400	255	400	
<b>14 Earnings Per Share (before extraordinary items) (not annualised):</b>					
(a) Basic	0.20	0.49	-0.56	-0.40	
(b) Diluted	0.20	0.49	-0.56	-0.40	
<b>15 Earnings Per Share (after extraordinary items) (not annualised):</b>					
(a) Basic	0.20	0.49	-0.56	-0.40	
(b) Diluted	0.20	0.49	-0.56	-0.40	

**Notes:**

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on August 22, 2017. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended June 30, 2017.
- The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.
- The Ind AS compliant figures for the corresponding quarter ended 30th June 2016, quarter ended 31st March 2017 and year ended 31st March 2017, including the reconciliation of profit/(loss) under Ind AS of the corresponding quarter/year with the profit reported under previous GAAP, have not been subjected to limited review or audit. However the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the affairs of the Company.

4. Reconciliation of Net Profit/(Loss) as reported earlier (referred to as Indian GAAP) vis-à-vis Ind AS is given below:

Particulars	Quarter ended 31st March, 2017	Quarter ended 30th June, 2016	Year ended 31st March, 2017
Net Profit/(Loss) as per previous Indian GAAP	19.50	-14.38	-15.88
Adjustments	0.00	0.00	0.00
Net Profit/(Loss) before other comprehensive income as per Ind AS	19.50	-14.38	-15.88
Add: Other Comprehensive Income (net of tax)	0.00	0.00	0.00
<b>Total comprehensive income as per Ind AS</b>	<b>19.50</b>	<b>-14.38</b>	<b>-15.88</b>

5. The Company operates only in single segment i.e. pharmaceuticals related activities

For, VIVANZA BIOSCIENCES LIMITED

Date : 22/08/2017  
Place : Ahmedabad





**Independent Auditors' Review Report**

To  
The Board of Directors,  
**Vivanza Biosciences Limited**

We have reviewed the accompanying statement of Consolidated Unaudited Financial results of **Vivanza Biosciences Limited** (The Holding Company) and its Subsidiary Company (The Holding Company and its Subsidiary Collectively referred to as "The Group") for the quarter ended 30<sup>th</sup> June, 2017, attached herewith, being submitted by the Holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015.

This statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Accounting Standard for Interim Financial Reporting (AS 25), Prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of the Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan & perform the review to obtain moderate assurance as to whether the statement is free of Material Misstatement. A review is limited primarily to Inquires of the Holding Company's personnel & analytical procedures applied to the financial data & thus provide less assurance than audit. We have not performed an Audit & accordingly we do not express an Audit opinion.

The statement includes the results of the wholly-owned subsidiary, **Vivanza Lifesciences Private Limited** (The Subsidiary Company)

We did not review the Interim Financial Results of the Subsidiary whose Interim Financial Information reflects NIL Revenue & Rs. 189,511/- Net Loss for the Quarter ended 30<sup>th</sup> June, 2017. This interim financial information of the subsidiary have not





CA

**G M C A & Co.**

Chartered Accountants

been audited by the any Auditors rather they have been signed & declared by the Directors of the Company & our report on the statement, in so far as it relates to the amounts and disclosures included in respect of the Subsidiary, is based solely on the Financial Statements signed & declared by the Board of Directors of the Subsidiary Company.

Based on our review conducted as above, and based on consideration of the signed & declared Financial Statements referred in the above paragraph, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, G M C A & CO.  
Chartered Accountants  
FRN: 109850W





CA. Amin G. Shaikh  
Partner

Membership No: 108894

Place: Ahmedabad

Date: 22<sup>nd</sup> August, 2017

## VIVANZA BIOSCIENCES LIMITED

(Formerly Known as IVEE INJECTAA LTD )

Registered Office: 702 "A" wing, Ashoka Chambers, Rasala Marg, Ellisbridge , Ahmedabad 380 006.

CIN : L24110GJ1982PLC005057

### STATEMENT OF CONSOLIDATE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017.

(Rs. in Lacs except per share data)

Particulars	Quarter Ended				Year Ended
	30/06/2017	31/03/2017	30/06/2016	31/03/2017	
	Unaudited	Audited	Unaudited	Audited	
<b>1 Income from Operations</b>					
(a) Revenue from operations	264.15	252.60	0.00		347.46
(b) Other Income	0.11	4.34	0.00		4.53
<b>Total Income</b>	<b>264.25</b>	<b>256.94</b>	<b>0.00</b>		<b>351.99</b>
<b>2 Expenses</b>					
(a) Cost of Materials consumed	0.00	0.00	0.00		0.00
(b) Purchase of stock-in-trade	64.32	365.08	0.00		487.77
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	162.64	-138.98	0.00		-181.00
(d) Employee benefits expense	11.03	0.91	9.93		41.63
(e) Finance Costs	8.56	4.24	0.00		4.28
(f) Depreciation and amortisation expense	0.00	-0.04	0.00		0.00
(g) Other expenses	11.55	12.93	4.45		30.46
<b>Total Expenses</b>	<b>258.09</b>	<b>244.14</b>	<b>14.38</b>		<b>383.14</b>
<b>3 Profit/(loss) before exceptional items and tax (1-2)</b>	<b>6.16</b>	<b>12.81</b>	<b>-14.38</b>		<b>-31.14</b>
<b>4 Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>		<b>0.00</b>
<b>5 Profit/(Loss) before tax (3-4)</b>	<b>6.16</b>	<b>12.81</b>	<b>-14.38</b>		<b>-31.14</b>
<b>6 Tax Expense</b>					
(a) Current tax	0.00	0.00	0.00		0.00
(b) Deferred tax	0.00	0.00	0.00		0.00
<b>Total Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>		<b>0.00</b>
<b>7 Profit / (Loss) for the period from continuing oprations (5-6)</b>	<b>6.16</b>	<b>12.81</b>	<b>-14.38</b>		<b>-31.14</b>
<b>8 Profit (Loss) from discontinuing oprations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>		<b>0.00</b>
<b>9 Tax Expense of discontinuing oprations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>		<b>0.00</b>
<b>10 Profit (Loss) from discontinuing oprations (after tax)(8-9)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>		<b>0.00</b>
<b>11 Share of Profit / ( Loss) of associates *</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>		<b>0.00</b>
<b>12 Minority Interest *</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>		<b>0.00</b>
<b>13 Other Comprehensive Income</b>					
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00		0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00		0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00		0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00		0.00
<b>Other Comprehensive Income for the period</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>		<b>0.00</b>
<b>14 Total Comprehensive Income for the period</b>	<b>6.16</b>	<b>12.81</b>	<b>-14.38</b>		<b>-31.14</b>
<b>15 Total Comprehensive Income attributable to :</b>					
Share of Profit / ( Loss) of associates *	0.00	0.00	0.00		0.00
Minority Interest *	0.00	0.00	0.00		0.00
<b>16 Paid-up equity share capital (Face value of ` 10/- each)</b>	<b>400</b>	<b>400</b>	<b>255</b>		<b>400</b>
<b>17 Earnings Per Share (before extraordinary items) (not annualised):</b>					
(a) Basic	0.15	0.32	-0.56		-0.78
(b) Diluted	0.15	0.32	-0.56		-0.78
<b>18 Earnings Per Share (after extraordinary items) (not annualised):</b>					
(a) Basic	0.15	0.32	-0.56		-0.78
(b) Diluted	0.15	0.32	-0.56		-0.78

**Notes:**

1. The above consolidate financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on August 22, 2017. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended June 30, 2017.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Ind AS compliant figures for the corresponding quarter ended 30th June 2016, quarter ended 31st March 2017 and year ended 31st March 2017, including the reconciliation of profit/(loss) under Ind AS of the corresponding quarter/year with the profit reported under previous GAAP, have not been subjected to limited review or audit. However the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the affairs of the Company.

4. Reconciliation of Net Profit/(Loss) as reported earlier (referred to as Indian GAAP) vis-à-vis Ind AS is given below:

Particulars	Quarter ended 31st March, 2017	Quarter ended 30th June, 2016	Year ended 31st March, 2017
Net Profit/(Loss) as per previous Indian GAAP	12.81	-14.38	-31.14
Adjustments	0.00	0.00	0.00
Net Profit/(Loss) before other comprehensive income as per Ind AS	12.81	-14.38	-31.14
Add: Other Comprehensive Income (net of tax)	0.00	0.00	0.00
Total comprehensive income as per Ind AS	12.81	-14.38	-31.14

5. The Company operates only in single segment i.e. pharmaceuticals related activities

For, VIVANZA BIOSCIENCES LIMITED

Date : 22/08/2017

Place : Ahmedabad

*Prestal*  
DIRECTOR

